Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

43 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa.
TEMPRANO ANRS 12136 Study Group; Danel C, Moh R, Gabillard D, Badje A, Le Carrou J, Ouassa T, Ouattara E, Anzian A, Ntakpé JB, Minga A, Kouame GM, Bouhoussou F, Emieme A, Kouamé A, Inwoley A, Toni TD, Ahiboh H, Kabran M, Rabe C, Sidibé B, Nzunetu G, Konan R, Gnokoro J, Gouesse P, Messou E, Dohoun L, Kamagate S, Yao A, Amon S, Kouame AB, Koua A, Kouamé E, Ndri Y, Ba-Gomis O, Daligou M, Ackoundzé S, Hawerlander D, Ani A, Dembélé F, Koné F, Guéhi C, Kanga C, Koule S, Séri J, Oyebi M, Mbakop N, Makaila O, Babatunde C, Babatounde N, Bleoué G, Tchoutedjem M, Kouadio AC, Sena G, Yededji SY, Assi R, Bakayoko A, Mahassadi A, Attia A, Oussou A, Mobio M, Bamba D, Koman M, Horo A, Deschamps N, Chenal H, Sassan-Morokro M, Konate S, Aka K, Aoussi E, Journot V, Nchot C, Karcher S, Chaix ML, Rouzioux C, Sow PS, Perronne C, Girard PM, Menan H, Bissagnene E, Kadio A, Ettiegne-Traore V, Moh-Semdé C, Kouame A, Massumbuko JM, Chêne G, Dosso M, Domoua SK, N'Dri-Yoman T, Salamon R, Eholié SP, Anglaret X. TEMPRANO ANRS 12136 Study Group, et al. Among authors: journot v. N Engl J Med. 2015 Aug 27;373(9):808-22. doi: 10.1056/NEJMoa1507198. Epub 2015 Jul 20. N Engl J Med. 2015. PMID: 26193126 Free article. Clinical Trial.
Effect of isoniazid preventive therapy on risk of death in west African, HIV-infected adults with high CD4 cell counts: long-term follow-up of the Temprano ANRS 12136 trial.
Badje A, Moh R, Gabillard D, Guéhi C, Kabran M, Ntakpé JB, Carrou JL, Kouame GM, Ouattara E, Messou E, Anzian A, Minga A, Gnokoro J, Gouesse P, Emieme A, Toni TD, Rabe C, Sidibé B, Nzunetu G, Dohoun L, Yao A, Kamagate S, Amon S, Kouame AB, Koua A, Kouamé E, Daligou M, Hawerlander D, Ackoundzé S, Koule S, Séri J, Ani A, Dembélé F, Koné F, Oyebi M, Mbakop N, Makaila O, Babatunde C, Babatunde N, Bleoué G, Tchoutedjem M, Kouadio AC, Sena G, Yededji SY, Karcher S, Rouzioux C, Kouame A, Assi R, Bakayoko A, Domoua SK, Deschamps N, Aka K, N'Dri-Yoman T, Salamon R, Journot V, Ahibo H, Ouassa T, Menan H, Inwoley A, Danel C, Eholié SP, Anglaret X; Temprano ANRS 12136 Study Group. Badje A, et al. Among authors: journot v. Lancet Glob Health. 2017 Nov;5(11):e1080-e1089. doi: 10.1016/S2214-109X(17)30372-8. Lancet Glob Health. 2017. PMID: 29025631 Free article. Clinical Trial.
Virological failure and drug resistance in West African HIV-infected adults who started ART immediately or deferred ART initiation.
Gabillard D, N'Takpé JB, Chaix ML, Kouame GM, Moh R, Toni TD, Le Carrou J, Karcher S, Badje A, Emieme A, Menan H, Danel C, Anglaret X, Eholié SP; Temprano ANRS 12136 study group. Gabillard D, et al. J Antimicrob Chemother. 2021 Sep 15;76(10):2666-2674. doi: 10.1093/jac/dkab225. J Antimicrob Chemother. 2021. PMID: 34533197 Clinical Trial.
Incidence of and risk factors for adverse drug reactions in a prospective cohort of HIV-infected adults initiating protease inhibitor-containing therapy.
Duval X, Journot V, Leport C, Chêne G, Dupon M, Cuzin L, May T, Morlat P, Waldner A, Salamon R, Raffi F; Antiprotease Cohort (APROCO) Study Group. Duval X, et al. Among authors: journot v. Clin Infect Dis. 2004 Jul 15;39(2):248-55. doi: 10.1086/422141. Epub 2004 Jul 1. Clin Infect Dis. 2004. PMID: 15307035
Viremia copy-years as a predictive marker of all-cause mortality in HIV-1-infected patients initiating a protease inhibitor-containing antiretroviral treatment.
Chirouze C, Journot V, Le Moing V, Raffi F, Piroth L, Reigadas S, Cassuto JP, Chêne G, Leport C, Hoen B; ANRS CO 08 Aproco-Copilote Study Group. Chirouze C, et al. Among authors: journot v. J Acquir Immune Defic Syndr. 2015 Feb 1;68(2):204-8. doi: 10.1097/QAI.0000000000000416. J Acquir Immune Defic Syndr. 2015. PMID: 25590273
Modeling changes in CD4-positive T-lymphocyte counts after the start of highly active antiretroviral therapy and the relation with risk of opportunistic infections: the Aquitaine Cohort, 1996-1997.
Binquet C, Chêne G, Jacqmin-Gadda H, Journot V, Savès M, Lacoste D, Dabis F; Groupe d'Epidémiologie Clinique du SIDA en Aquitaine. Binquet C, et al. Among authors: journot v. Am J Epidemiol. 2001 Feb 15;153(4):386-93. doi: 10.1093/aje/153.4.386. Am J Epidemiol. 2001. PMID: 11207157
Four year follow-up of simplification therapy with once-daily emtricitabine, didanosine and efavirenz in HIV-infected patients (ALIZE ANRS 099 trial).
Gallien S, Journot V, Rozenbaum W, Yéni P, Morlat P, Poizot-Martin I, Reynes J, Reliquet V, Leclercq P, Simon F, Chêne G, Molina JM; ALIZE (ANRS 099) Study Group. Gallien S, et al. Among authors: journot v. J Antimicrob Chemother. 2011 Jan;66(1):184-91. doi: 10.1093/jac/dkq395. Epub 2010 Oct 28. J Antimicrob Chemother. 2011. PMID: 21036772 Clinical Trial.
43 results